Latest MS research news

Latest MS research news | 07 January 2014

Effect of daclizumab high-yield process in patients with highly active relapsing-remitting MS

This analysis looked at the effects of DAC in patients with highly active RRMS and those with less active RRMS. There was no evidence that disease activity at baseline modified the effect of DAC on MS activity as treatment effects were similar in both subgroups.

From MSIF

Latest MS research news | 17 December 2013

Cerebrospinal fluid pleocytosis in multiple sclerosis patients with lesions showing reduced diffusion

The researchers in this study looked at changes in diffusion parameters on MRI in MS subjects during the acute phase of MS relapses and the associated changes in the cell count in the cerebrospinal fluid (CSF).

From MSIF

Latest MS research news | 17 December 2013

Milder multiple sclerosis course in patients with concomitant inflammatory bowel disease

Patients with IBD have an increased risk of developing MS and MS patients have an increased risk of developing IBD. This study showed that patients with MS and IBD appear to have a milder MS disease course without any influence on IBD course.

From MSIF

Latest MS research news | 17 December 2013

Improved differentiation between MS and vascular brain lesions using FLAIR* at 7 Tesla

This study looked at a new MRI technique on the new high powered MRI scanner (7 Tesla), and investigated if this new technique helped to differentiate MS lesions from vascular lesions in the brain.

From MSIF

Latest MS research news | 11 December 2013

Long-term effects of dalfampridine in patients with multiple sclerosis

This study looked at the short and long term effects of treatment with dalfampridine on motor and cognitive measures in MS patients over a nine to 12 month period.

From MSIF

Latest MS research news | 11 December 2013

Smokers run increased risk of developing anti-natalizumab antibodies

This study showed that smoking during or close to the time of treatment with natalizumab (Tysabri) was associated with an increased risk of developing antibodies against natalizumab.

From MSIF

Latest MS research news | 11 December 2013

Effects of Bacille Calmette-Guerin after the first demyelinating event in the CNS

This study showed that the BCG vaccine, when compared to placebo, was associated with a definite reduction in the development of gadolinium-enhancing lesions on MRI in subjects with a clinically isolated syndrome.

From MSIF

Latest MS research news | 03 December 2013

Lesional-targeting of neuroprotection to the inflammatory penumbra in experimental multiple sclerosis

This study provides further evidence that sodium blockers have the potential to limit nerve loss in the progressive phase of MS in the animal model. By targeting this class of agent, this may slow neurodegeneration in MS.

From MSIF

Latest MS research news | 03 December 2013

Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis

This study looked at specific types of RNA (called micro RNAs), which are involved in the regulation of gene expression. The researchers found that levels of these in the blood were decreased in MS patients compared to controls.

From MSIF

Latest MS research news | 03 December 2013

Characteristics influencing therapy switch behavior after suboptimal response to first-line treatment in patients with multiple sclerosis

This study compared demographic and clinical characteristics of patients with RRMS who did or did not switch disease modifying therapy after experiencing an MS-related clinical event.

From MSIF
 

Latest MS research news

Main MS research areas

Challenges of MS research

Atacicept in multiple sclerosis: a randomised, placebo-controlled, double-blind, phase 2 trial